By now atherothrombotic disorders have become one of the most endangering public health problems of the civilized world. Simultaneously, antithrombotic therapeutic guidelines have been rewritten by the results of the thrombosis research and the use of new antithrombotic drugs. New drugs like direct thrombin inhibitor hirudins or platelet glycoprotein IIb/IIIa receptor inhibitors have become part of combined antithrombotic therapy in acute coronary syndromes. Platelet cyclooxygenase-inhibitors combined with platelet ADP-receptor antagonists are frequently used by interventional cardiologists. Guidelines for anticoagulant therapy in atrial fibrillation have been refined. Conventional unfractionated heparins have started to be replaced by low molecular weight heparins in most fields of cardiology. Schematic representation of the antithrombotic therapy in cardiovascular diseases is intended to be demonstrated on the next pages.
|Translated title of the contribution||Antithrombotic therapy in cardiovascular diseases|
|Number of pages||7|
|Publication status||Published - Dec 1 1999|
ASJC Scopus subject areas